PharmaSGP Holding SE
PSG
ISIN DE000A2P4LJ5 / Valor 55294050
PharmaSGP Holding SE
UMushroom community rating:
About company
PharmaSGP Holding SE is a consumer health company specializing in natural non-prescription pharmaceuticals and healthcare products, primarily sold through pharmacies. The company's core brands focus on chronic indications such as pain and age-related ailments, with leading products like RubaXX® and Restaxil® for pain relief, as well as DESEO® and Neradin® for men's health. Recently, PharmaSGP expanded its portfolio with the acquisition of OTC brands like Baldriparan®, Formigran®, Spalt®, and Kamol®, further solidifying its position in the pain therapy and sleep disorder categories. With a strategic focus on expanding its "Health Brands" category and entering new markets in Europe, PharmaSGP aims to continue its growth trajectory through both organic expansion and strategic acquisitions.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (09.11.2025):
PharmaSGP Holding SE’s latest preliminary Q1 2025 earnings update—set against the backdrop of its expanding presence in the European natural non‐prescription pharmaceuticals market—suggests a continuation of robust revenue growth, even as operating margins have come under modest pressure. While detailed Q1 numbers are expected with the upcoming interim statement, recent half‐year data provides a useful lens on the company’s performance trends.
Revenue Growth
For H1 2025, PharmaSGP Holding SE reported revenues of €66.0 million, representing a 13.0% growth compared to the previous half-year period. This growth underscores the company’s success in leveraging its extensive portfolio of natural OTC products and its pan‐European expansion strategy.
Operating Profitability
Adjusted EBITDA for H1 2025 was €16.7 million, translating to an EBITDA margin of 25.3%. In parallel, adjusted EBIT was recorded at €11.9 million with an 18.0% margin. These figures indicate a slight compression in operating margins relative to prior periods, signaling increased cost pressures as the company invests in growth and market expansion.
Financial Stability
The balance sheet reflects a total of €115.2 million in assets and an equity ratio of 34.1% for H1 2025, demonstrating a solid capital foundation that supports PharmaSGP’s ongoing strategic initiatives and scalability in the competitive consumer health sector.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
424 M
Market cap (USD)
3,665
Daily traded volume (Shares)
24.6 / 23.8
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
